908 Devices, which manufactures analytical devices for chemical and biomolecular analysis, was awarded a technical project grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). According to a company spokesperson, the award will fuel continued development of at-line bioreactor process analytics, a collaboration between 908 Devices, MilliporeSigma, the University of North Carolina at Chapel Hill, North Carolina State University, and other biopharmaceutical manufacturers.

The mission of NIIMBL is to accelerate biopharmaceutical manufacturing innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a biopharmaceutical manufacturing workforce. In concert with that mission, this project tackles the challenge of monitoring metabolic attributes in bioreactors with a fraction of the test complexity and sample volume of what is required by today’s technology, said Kevin Knopp, PhD, CEO and co-founder of 908 devices. The results will offer insight into cell growth and critical process attributes integral to biopharmaceutical development, he added.

This site uses Akismet to reduce spam. Learn how your comment data is processed.